# DES versus BMS bij acuut MI met cardiogene shock

*geplaatst 2017-08-01 · Algemeen · Heart (British Cardiac Society) · doi 10.1136/heartjnl-2016-310403 · https://hartvaat.nl/2017/08/01/des-versus-bms-bij-acuut-mi-met-cardiogene-shock/*

Studie die drug-eluting stents vergeleek met bare-metal stents bij patiënten met acuut MI gecompliceerd door cardiogene shock.

## English: Drug-eluting stents versus bare-metal stents in acute myocardial infarction with cardiogenic shock.

This study compared drug-eluting with bare-metal stents in patients with acute MI complicated by cardiogenic shock, testing whether the benefits of DES extend to the most hemodynamically unstable patients.

## Abstract (original, from the publication)

OBJECTIVES: The aim of the present study was to assess the outcome of patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) receiving drug-eluting stents (DES) compared with bare-metal stents (BMS). Data comparing these two stent technologies in AMI with CS were limited. METHODS: A total of 783 patients with AMI and CS undergoing early revascularisation were included in the randomised Intra-aortic Balloon Pump in Cardiogenic Shock II trial (n=600) and the associated registry (n=183). Patients receiving no stent or both, DES and BMS, were excluded. Primary end point was the composite of 1-year mortality or re-AMI. RESULTS: Of the total cohort, 652 (83%) patients received either solely DES or BMS and were included in the present analysis. Of these, 276 (42%) patients received DES and 376 (58%) received BMS. After adjustment for baseline characteristics, there was no significant difference between DES and BMS regarding the primary end point (HR 0.83 (CI 0.64 to 1.06); p=0.14). There was an independent association of BMS use with older age, atrial fibrillation and coronary single-vessel disease. DES use was associated with prior known dyslipidaemia, baseline haemoglobin level, anterior AMI and treatment at frequently enrolling centres. CONCLUSIONS: Despite the frequent use of DES nowadays, a substantial number of patients were treated by BMS in AMI complicated by CS. After adjustment for risk factors, the 1-year outcome of patients treated by DES compared with BMS was similar. TRIAL REGISTRATIONNUMBER: www.clinicaltrials.gov: NCT00491036.

Auteurs: Jakob Ledwoch, Georg Fuernau, Steffen Desch, Ingo Eitel, Christian Jung, Suzanne de Waha, Janine Poess, Steffen Schneider, Gerhard Schuler, Karl Werdan, Uwe Zeymer, Holger Thiele

---
Bron: Heart (British Cardiac Society), https://doi.org/10.1136/heartjnl-2016-310403. Bijgewerkt 2026-07-03T13:26:06Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.